|
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27). |
|
|
Honoraria - Amgen; Lilly; Lilly; Roche; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Amgen; Roche; Roche; Sanofi |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Ipsen; Ipsen; Lilly; Lilly; Novartis; Novartis; Roche; Roche |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Amgen; Bayer; Lilly; Roche |
|
Travel, Accommodations, Expenses - Amgen; Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Merck; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Consulting or Advisory Role - Ipsen |
Research Funding - Roche/Genentech (Inst) |
|
|
Honoraria - Amgen; Celgene; Lilly; Merck; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Merck; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Sanofi |
Speakers' Bureau - Roche/Genentech |
Research Funding - Bayer (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Merck Serono |
Consulting or Advisory Role - Roche; Sanofi |
|
|
Honoraria - Amgen; Bayer; Merck Serono; Sanofi |
|
|
Honoraria - Amgen; Bayer; Celgene; Lilly; Merck; Novartis; Roche; Sanofi |
Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Merck; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Sanofi |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Sanofi |
Research Funding - Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Amgen |
|
|
Honoraria - Bayer; Merck; Roche |
Consulting or Advisory Role - Bayer; Merck; Roche |